Stock Ratings / Health Care / INTS / forecast

PASG (51) INAB (38) ATYR (44) BCDA (49) ⌘ Pro Terminal →

Intensity Therapeutics Inc. (INTS) 12-Month Stock Forecast & Price Target Cone

$3.34 -1.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Intensity Therapeutics Inc. (INTS) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $10.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INTS)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your INTS Position Size: $10,000

Shares at $3.34: 2994.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.47

$7,395

$-2,605 (-26.0%)

12M Consensus BaseTarget $3.17

$9,491

$-509 (-5.1%)

12M Bull Case BreakoutTarget $18.56

$55,569

+$45,569 (+455.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$3	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$17	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INTS)

✓Walkthrough of INTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.89%▼ DESCENDING CHANNEL

2026-10-30O $3.41H $3.45L $3.21C $3.34VOL 16.1K

RES: $5.06SUP: $2.77SMA50: $3.77SMA200: $5.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INTS Butterfly Map → + Track INTS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INTS)

Health Care Rank #425 of 1016 ⚔️ PASG vs INTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INTS vs. PASG, INAB, ATYR, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Intensity Therapeutics Inc. (INTS) ranks #425 by composite RQD confidence (47/100, grade D) and #891 by equity capitalization ($10.9M). Within this direct 5-issuer industry benchmark cohort, INTS leads on earnings valuation at N/A trailing P/E, while INTS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PASG currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with INTS at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INTS ACTIVE Intensity Therapeutics Inc.	D	47/100	—	—	-35.0%	-1.18%	$10.9M	Benchmark Subject
PASG Passage Bio Inc.	D	51/100	—	—	-35.0%	+5.71%	$11.3M	/pasg-vs-ints →
INAB IN8bio Inc.	D-	38/100	—	—	-35.0%	-3.91%	$9.7M	/inab-vs-ints →
ATYR aTyr Pharma Inc.	D	44/100	—	—	-35.0%	+4.56%	$13.5M	/atyr-vs-ints →
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-ints →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001567264

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Intensity Therapeutics Inc. (INTS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.6M, operating cash flow of -$9.2M, and free cash flow of -$9.2M (+39.3% YoY). On the balance sheet, INTS closed FY2025 with $14.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.6M	-$9.2M	-$9.2M	$14.1M	—
FY2024 (FY)	2024-12-31	$0	-$16.3M	-$15.2M	-$15.2M	$4.8M	—
FY2023 (FY)	2023-12-31	$0	-$10.5M	-$7.2M	-$7.2M	—	—

3. INTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Intensity Therapeutics Inc. (NASDAQ: INTS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.34 (-1.18% 1D, market cap $10.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INTS ranks #425 in composite RQD confidence.

How does INTS compare to PASG and INAB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INTS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PASG (Passage Bio Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -35.0%, cap $11.3M) and INAB (IN8bio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $9.7M). Among the 5-stock peer group, INTS leads on earnings multiple (N/A) while INTS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INTS?

Per INTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001567264), Intensity Therapeutics Inc. generated $0 in revenue, -$11.6M in net income, and -$9.2M in free cash flow against $14.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INTS trading relative to its 50-day, 200-day, and 52-week technical levels?

INTS last traded at $3.34 (-1.18% on volume of 7,656 shares), positioning the stock -11.41% below its 50-day simple moving average ($3.77) and -36.02% below its 200-day simple moving average ($5.22). Across its 52-week range of $3.00 to $17.68, INTS sits at the 2.3% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.92 to $3.76).

INTS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is INTS's 12-month stock price target?

Intensity Therapeutics Inc. (INTS) carries a 12-month consensus base price target of $3.17 (-5.1% from $3.34), with a bull-case target of $18.56 and a bear-case floor of $2.47.

Is INTS stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates INTS D (Sell — SELL) with an RQD Confidence score of 47/100.

Direct Sub-Reports: INTS RQD Cockpit INTS 12M Forecast INTS Earnings & Move INTS Dividends & DRIP INTS Insiders & 13F INTS Whale Options INTS Profit Sankey INTS News & Why